LongevityCellular Health

Vilon

Synthetic thymic dipeptide for immunoregulatory & regenerative research

Overview

Vilon (Lys-Glu) is a synthetic dipeptide originally developed in thymic peptide research and categorized among cytogen / bioregulatory peptides. It has been modeled structurally and studied in preclinical and in vitro systems for its effects on immune cells, inflammatory processes, and tissue aging. Supplied as a lyophilized peptide for research use only.

Chemical Information

IUPAC Name
L-Lysyl-L-glutamic acid
Sequence
Lys-Glu
Molecular Mass
275.3 Da
Formula
C11H21N3O5
Vilon Chemical Structure

Mechanism of Action

Functions as a synthetic thymic dipeptide (Lys-Glu) and chromatin-modifying bioregulator. Mechanistically, it acts as an epigenetic modulator by inducing the 'unrolling' (deheterochromatinization) of silent chromatin in aged lymphocytes. This structural change reactivates ribosomal genes and protein synthesis pathways, effectively restoring the proliferative capacity of the immune system (reversing immunosenescence). Additionally, it modulates the NF-κB inflammatory loop in monocytes (THP-1 cells), inhibiting the release of TNF-α and IL-6 during immune stress. In radiation models, it prevents the atrophy of the thymus and spleen, preserving immune organ integrity against oxidative and apoptotic damage.

Potential Research Fields

ImmunosenescenceChromatin remodelingRadiation protectionAnti-agingInflammation modulation

Recent Research

Recent research (2024–2025 focus) highlights Vilon’s unique role as a 'genomic stabilizer' for the aging immune system. Unlike simple immunostimulants, Vilon is investigated for its ability to physically alter chromatin structure in senescent T-cells, making silent repair genes accessible again. A key study in human THP-1 monocytes demonstrated its dual ability to suppress 'cytokine storm' markers (TNF-α, IL-6) while maintaining healthy cell proliferation. Furthermore, radiation biology studies have positioned Vilon as a potent radioprotector, capable of shielding thymic and splenic tissue from accelerated aging and atrophy following oxidative stress insults.

Bibliography / Scientific References

Related Peptides

Peptide Information Guide
Administration Type
Injectable (Subcutaneous)

Injectable administration protocol for research.

Vial Strength
20mg
Reconstitution
Reconstitute with 2ml bacteriostatic water
Dosage Options
1 mg
1x daily
Standard research dose (10 units of 10mg/ml solution)
10 units
1x daily
Volume-based reference for 2ml reconstitution
Schedule
1x daily
Timing: One specific day.
Duration
According to the Doctor
Potential Side Effects
Injection site reaction
lowoccasional
Research Use Only

This information is for research purposes only. Always consult with a healthcare professional before starting any peptide protocol. Individual responses may vary, and proper medical supervision is recommended for all peptide therapies.